PTH suppression by calcitriol does not predict off-target actions in experimental CKD

Bruno A. Svajger1 | Cynthia M. Pruss1 | Kimberly J. Laverty1 | Jason G. E. Zelt2,3 | Glenvile Jones1 | Martin Kaufmann1 | Martin Petkovich1 | Rachel M. Holden1,4 | Michael A. Adams1

1Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON, Canada
2Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
3Molecular Function and Imaging Program, The National Cardiac PET Centre, and the Advanced Heart Disease Program, Department of Medicine, University of Ottawa Heart Institute and University of Ottawa, Ottawa, Ontario, Canada
4Department of Medicine, Queen’s University, Kingston, Ontario, Canada

Correspondence
Bruno A. Svajger, Department of Biomedical and Molecular Sciences, Botterell Hall, Queen’s University, 18 Stuart Street, Kingston K7L 3N6, Ontario, Canada.
Email: bsvajger@qmed.ca

Funding information
Canadian Institutes of Health Research

Abstract
Vitamin D receptor agonist (VDRA) therapy for PTH suppression is a mainstay for patients with severe CKD. Calcitriol (1,25-(OH)2D3) is a former first-line VDRA in CKD treatment. However, a consequence of its use in CKD is accelerated vascular calcification (VC). An experimental CKD model was used to determine whether altering the calcitriol delivery profile to obtain different PTH suppression levels could improve vascular health outcomes. High adenine diet (0.25%) was used to generate experimental CKD in rats. CKD rats were treated using different calcitriol dosing strategies: (a) 20 ng/kg SD (n = 8), (b) 80 ng/kg SD (n = 8), (c) 5 ng/kg QID (n = 9), or (d) 20 ng/kg QID (n = 9). Multiple targets of calcitriol were assessed which include arterial calcium and phosphate as well as circulating calcium, phosphate, PTH, FGF-23, VWF, and vitamin D metabolome. PTH suppression occurred dose-dependently after 1-week calcitriol treatment (P < .01), but the suppressive effect was lost over time. Both VC and circulating FGF-23 increased > 10× in all calcitriol-treated rats (P < .05 and P < .001, respectively); similarly, circulating VWF increased at all time points (P < .05). Ad-hoc analysis of CKD morbidities in treated rats indicated no differences in negative outcomes based on PTH suppression level (minimal-, target-, and over-). Comparing different calcitriol dosing strategies revealed the following: (a) despite initial calcitriol-influenced PTH suppression across all treatments, the ability to continually suppress PTH was markedly reduced by study conclusion and (b) PTH suppression level is not an adequate proxy for improvements in overall CKD morbidity. These findings show (a) a more holistic approach to evaluate CKD treatment efficacy aside from PTH suppression is needed and (b) that other VDRA therapies should be examined in CKD treatment.

KEYWORDS
Calcitriol, CKD, PTH suppression, vascular pathology

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.

Received: 11 May 2020 | Accepted: 12 May 2020
DOI: 10.1002/prp2.605
https://doi.org/10.1002/prp2.605
Vitamin D insufficiency, as measured by 25-OH-D₃ (calcifediol) levels below 30 ng/mL, is a hallmark of chronic kidney disease (CKD).¹ CKD also results in reduced conversion of calcifediol to its active form 1,25-(OH)₂D₃ (calcitriol), due to loss of expression and/or function of renal CYP27B1. This vitamin D deficiency commonly results in hypocalcaemia as calcitriol is the primary mediator of calcium absorption from the gastrointestinal tract. Together lower calcitriol levels accompanied by hypocalcaemia stimulate parathyroid hormone (PTH) release to restore calcium levels by stimulating resorption of bone calcium and phosphate stores.³ Vitamin D levels further decrease as CKD progresses, leading to a worsening cycle of increasing secondary hyperparathyroidism and osteodystrophy.

The current Kidney Disease Improving Global Outcomes (KDIGO) recommendations for rectifying abnormalities in the vitamin D metabolome and mineral-bone axis focus on the supplementation of calcitriol and active vitamin D analogs to target severe and progressive hyperparathyroidism (SHPT).⁶–⁸ These recommendations are based on observations that VDR agonists are the mainstay of SHPT management, being tested in the present study, is that the adverse effects of calcitriol (hypercalcemia, elevated FGF-23, and PTH over-suppression) are a consequence of the pharmacologic strategy of once-daily bolus dosing. Studies examining the use of a modified release calcifediol dosing regimen demonstrated marked reductions in PTH and higher levels of circulating calcitriol without causing hypercalcemia/hyperphosphatemia or significantly increasing FGF-23.¹²⁻¹⁴ To test whether similar benefits could be derived with calcitriol dispersed over a broader time period, this study examined if altering the calcitriol dose or frequency of administration so as to moderate peak levels would improve outcome measures of PTH, FGF-23, and VC.

Two different dosing levels were tested (20 and 80 ng/kg/day) using strategies of either once a day (SD) or divided into smaller doses four times a day (QID) in rats with an experimental form of CKD. The hypothesis was that treatment with lower dose of calcitriol, given in four divided doses (4 x 5 ng/kg/day), would be the most effective strategy for achieving target levels of circulating PTH while minimizing negative effects on vascular health and other mineral-hormonal factors. Given that VDR agonists are the mainstay of SHPT management in many countries, strategies that could enhance their safety profile are warranted.

2 | MATERIALS AND METHODS

2.1 | Animal model

All animal procedures were performed in accordance with the guiding principles of the Canadian Council on Animal Care and were approved by the Queen’s University Animal Care Committee.
Adult male Sprague Dawley rats (n = 34, 14 weeks of age; Charles River®, Montreal, QC) were individually housed and maintained on a 12-hour light/dark cycle. Animals were acclimatized for 1 week prior to study commencement. From the beginning of the study (Week 0, Day 0) onwards, CKD was generated using a specially formulated diet (0.25% adenine, 1% phosphate, 1% calcium, and 6% protein),12 Navid24 that was provided throughout the entirety of the experiment. After 3 weeks of CKD induction, rats were stratified (Week 4, Day 22) into one of five calcitriol treatment groups: 0 ng/kg (CKD-Utreated, n = 8), 20 ng/kg SD (20D SD, n = 8), 5 ng/kg QID (SD QID, n = 9), 80 ng/kg SD (80D SD, n = 8), and 20 ng/kg QID (20D QID, n = 9) based on serum creatinine to ensure equivalent CKD status across groups. Rats were provided with calcitriol for three full weeks (Week 6, Day 41), then during the fourth week on treatment (Week 7) rats were anesthetized and sacrificed with blood and tissues collected for analysis. A control group (n = 6) was given standard rat chow (LabDiet 5001, Ren’s Pets Depot, Oakville, ON, Canada) for the duration of the experiment and sacrificed with CKD animals. All rats received water ad libitum for the duration of the study.

2.2 | Calcitriol dose

Calcitriol dosage is approximately 15-50 ng/kg/day in the rat to mimic human clinical therapeutic levels. From our previous studies, the 80 ng/kg/day was selected to generate a phenotype consisting of vascular calcification, mild hypercalcemia, and over-suppression of PTH.15,16 The 20 ng/kg/day dosage previously appeared to avoid these adverse outcomes. The dosing schedule of SD vs QID was to determine whether the magnitude of bolus or 24-hour exposure changed outcomes, with QID being chosen as to best approximate to a steady-state dosing based off of calcitriol's half-life of approximately 6 hours.25

2.3 | Serum biochemistries

Blood samples from saphenous vein were collected in capillary tubes for serum and heparin plasma at baseline, 3 and 5 weeks of treatment, and at sacrifice. Plasma PTH and C-terminal FGF-23 (cFGF-23) levels were measured using enzyme-linked immunosorbent assays (ELISA; 60-2500, 60-6300, Immutopics®). Circulating VWF levels were measured via ELISA per manufacturer’s protocol (DAKO, Carpinteria). Creatinine levels were measured with QuantiChrom Creatinine Assay Kit (DICT-500; BioAssay Systems) while serum calcium and phosphate were determined colorimetrically using the o-cresolphthalein complexone assay (540 nm, Sigma-Aldrich Canada Co.) and malachite green methods (650 nm), respectively.26 In brief, the o-cresolphthalein colour reagent forms a purple complex with the calcium in the samples and the malachite green reagent involves the formation of a green complex between malachite green, molybdate, and free phosphate.

2.4 | Vessel calcification

Aorta were demineralized in 50 μL/mg tissue 1.0 N hydrochloric acid at 4°C for 24 hours. Tissue was then removed, and homogenate analysed for calcium and phosphate content using the assays for serum calcium and phosphate.15,16,26

2.5 | Measurement of 1,25-(OH)2-D3 and metabolites

Serum 25-(OH)-D3 and 24, 25-(OH)2-D3 were quantified by LC-MS/ MS, using previously published methods27,28 (except that the starting volume of serum was reduced to 25 μL and diluted with 275 μL of water after addition of internal standard (mixture of 6d6-25-OH-D3 and 6d6-24-25-(OH)2-D3) where an equivalent of 19 μL of serum was analyzed per injection. Vitamin D metabolite levels were determined in individual animals. 1,25-(OH)2-D3 levels were similarly quantified using LC-MS/MS as previously established.29,30

2.6 | Statistical analysis

Statistical analysis was performed using GraphPad Prism 7.0 (GraphPad Software). Two-way ANOVA was performed with ad-hoc Bonferroni correction to identify interactions while linear regressions were employed to identify associations. Significance was defined as P < .05.

3 | RESULTS

3.1 | Induction of chronic kidney disease

We used a modification of the standard adenine rat model of CKD for these studies.31 Providing adenine in the diet over 7 weeks (0.25% adenine, 1% phosphate) increased circulating creatinine (Table 1), phosphate (Table 1), PTH (Figure 1A), and FGF-23 (Figure 1B) to levels indicative of moderate (<300 umol/L creatinine) to severe CKD (>300 umol/L creatinine). This model generates a stably progressing CKD phenotype through the accumulation of adenine metabolite crystals, 2-dihydroxyadenine, within the nephric tubular interstitium. These crystals progressively accumulate and damage nephrons, reducing kidney function. In these studies, there were no significant differences between treatment groups in terms of CKD generation, including the non-treated CKD (Figure 1D). As expected, this modified adenine-based dietary protocol caused a slight reduction in bodyweight during the induction of CKD (Table 1).15,16,26,32 After 4 weeks on the adenine diet, CKD rats were stratified, based on circulating creatinine, into five calcitriol treatment groups with similar overall severity of CKD: (a) No treatment (0 ng/kg), (b) 5 ng/kg 4 times/day (SD QID, n = 9), (c) 20 ng/kg/ once/day (20D SD, n = 8), (d) 20 ng/kg 4 times/day (20D QID, n = 9), and (d) 80 ng/kg once/day (80D SD, n = 8).
into four smaller doses (5 or 20 ng/kg QID). All groups suppressed PTH significantly for each dose similarly declined regardless of dosing regimen.

Following the sorting of groups according to creatinine, there were no between-group differences regarding bodyweight, PTH, or FGF-23.

3.2 Influence of calcitriol on the CKD phenotype

Compared to untreated CKD animals, calcitriol treatment produced significant elevations (27%-53%) in serum calcium (Table 1) without significantly changing serum phosphate (Table 1).

Within 1 week of calcitriol treatment, PTH was significantly suppressed in all calcitriol groups relative to untreated rats (Figure 1A). With 80 ng/kg/day treatments providing significantly greater suppression than the 20 ng/kg/day treated groups (Figure 1A). The effectiveness of calcitriol to suppress PTH in all treatment regimens was significantly reduced between 1 and 3 weeks.

In contrast, there was no marked attenuation of the effect of calcitriol on FGF-23, which significantly increased over time for both daily doses (Figure 1B). Notably, rats receiving 80 ng/kg/day had significantly higher overall FGF-23 levels compared to 20 ng/kg/day (Figure 1B).

3.3 Effect of dividing calcitriol doses on circulating biomarkers of CKD

No significant differences in elevated circulating phosphate (Table 1), calcium (Table 1), PTH (Figure 1A), or FGF-23 (Figure 1B) were observed comparing single daily dose (20 or 80 ng/kg SD) vs subdivision into four smaller doses (5 or 20 ng/kg QID). All groups suppressed PTH to a greater extent at the earlier time point compared to the 3-week time point. That is, despite continuous dosing the capacity to suppress PTH for each dose similarly declined regardless of dosing regimen.

3.4 Measures of vascular damage and endothelial dysfunction

Aortic tissue accrual of both calcium and phosphate was significantly increased in all calcitriol-treated groups compared to untreated CKD (Figure 2A,B). However, no differences were detected between the 20 and 80 ng/kg total dose groups or between the single vs four-time dosing regimens (SD vs QID). Furthermore, all calcitriol-treated rats had a significantly greater proportion of animals with von Kossa stainable VC (phosphate > 50 nmol/mg tissue, calcium > 80 nmol/mg tissue) compared to untreated CKD rats. The increase in vessel mineral levels corresponds to the development of medial layer vascular calcification as visualized via von Kossa stain (Figure 3).

Von Willebrand Factor (VWF), an endothelial factor released, in part, in response to shear force, was significantly elevated as CKD progressed (Figure 2C). Treatment with calcitriol led to significant elevations in VWF compared to non-treated CKD rats after only 1 week of treatment, with further near two-fold increases compared to untreated-CKD as treatment continued to study endpoint. Linear regression analysis revealed there was a significant association ($r^2 = .32, P < .001$, Figure 2D) between aortic phosphate content and the corresponding increased level of VWF at the end of the experiment.

3.5 Alterations to CKD biomarkers and vascular health relative to PTH suppression status

The therapeutic target for PTH suppression is two to nine times above the upper limit of the reference range for the PTH assay being used. As a proxy, we employed a therapeutic target that was two to nine times the circulating PTH average in healthy control rats (mean = 224.12 pg/mL; range: 448.24-2017.07 pg/mL), as to create an internal standardized reference range. Neither altering the magnitude of the daily dose (20 vs 80 ng/kg/day) nor changing the frequency of administration (SD vs QID) led to differences in attaining therapeutic PTH suppression, where 41.2% of animals on 20 ng/kg/day vs 46.7% on 80 ng/kg/day attained therapeutic PTH target.

An ad-hoc sub-analysis of all calcitriol-treated CKD rats was performed to determine the effects of differing levels of PTH suppression. Treated rats were stratified based on circulating
PTH levels: Minimal Suppression (MS, PTH > 2017.17 pg/mL, n = 13), Target (448.24 < PTH < 2017.07 pg/mL, n = 14), and Over-Suppression (OS, PTH < 448.24 pg/mL, n = 5). In comparing these groups, CKD rats attaining Target or OS levels were more likely to have significantly lowered serum creatinine than untreated CKD and MS groups (Table 2). Despite the differences in PTH suppression across the various calcitriol dose groups, the impact on FGF-23 was consistently and similarly elevated across all treatment groups (Figure 4B). The increased development of VC during calcitriol treatment was also not altered when assessed according to PTH suppression status (Figure 4C,D). Furthermore, there were no between-group differences to increases in circulating VWF based on suppression status (MS = 3.03 ± 0.25 U/mL, Target = 3.02 ± 0.19 U/mL, OS = 3.15 ± 0.15 U/mL).

3.6 | Calcitriol dosing effect on Vitamin D and Vitamin D-related metabolites

Compared to untreated CKD, calcitriol treatment resulted in marked decreases to both circulating 25-OH-D₃ and 24, 25-(OH)₂D₃ (Figure 5A,B). Furthermore, the ratio of 24, 25-(OH)₂D₃ to 25-OH-D₃ was mildly decreased for the two higher doses of calcitriol with significant suppression in the 80 ng/kg per day vs 20 ng/kg per day treated rats (Figure 5C). Circulating 1,25-(OH)₂D₃ was significantly elevated in all calcitriol-treated rats compared to untreated CKD with significantly higher levels in rats given 80 vs 20 ng/kg/day (Figure 5D).

Further analysis, based on PTH suppression status, showed significant decreases in circulating 25-(OH)D₃ in Target and OS groups, but not the MS group (Figure 6A). Although a similar pattern was
noted for 24,25-(OH)₂D₃, only the decline in the OS group was significant compared to CKD (Figure 6B). The ratio of 25-OH-D₃ to 24,25-(OH)₂D₃ was not significantly different between the three groups divided by suppression status (Figure 6C). Interestingly, 1,25-(OH)₂D₃ levels were similarly elevated in all calcitriol treatment groups regardless of the impact on PTH suppression (Figure 6D).

4 | DISCUSSION

This study sought to determine whether implementing a divided-dose strategy for calcitriol, the direct-acting vitamin D receptor (VDR) agonist, in the management of SHPT in experimental CKD, would ameliorate the adverse changes of this treatment to the mineral-bone disease phenotype. The findings revealed that all calcitriol treatment protocols increased vascular calcification (VC), circulating fibroblast growth factor-23 (FGF-23) and von Willebrand Factor (VWF), as well as similarly modifying the vitamin D metabolome, but without providing proportional and sustained parathyroid hormone (PTH) suppression. Specifically, comparing two daily single dosing strategies (20 vs. 80 ng/kg/day) to a divided dosing strategy (QID) revealed that (a) despite all treatments producing significant short-term suppression of PTH, in a dose-dependent manner, there was marked attenuation of PTH suppression in all groups by week three of treatment and (b) stratification by level of PTH suppression (minimal-, target-, and over-) did not differentiate for the impact on VC, endothelial dysfunction, hypercalcemia or increased FGF-23, although there was a moderate differential impact on the vitamin D metabolome.

A critical finding was the significant loss of PTH responsiveness with calcitriol treatments between 1 and 3 weeks. Previous studies suggest that a potential cause of this progressive attenuation of response is a CKD-induced decline in VDR density in the parathyroid glands possibly mediated by hyperplasia. Specifically, in experimental models of CKD, pharmacological inhibition of parathyroid gland hyperplasia preserved both VDR levels and the associated calcitriol-based PTH suppression.³³,³⁴ Experimentally, the stimulus for parathyroid gland hyperplasia has been reported to be a combination of uremia and hyperphosphatemia.³³,³⁵–³⁷ The current findings agree with this concept since both the severity of hyperphosphatemia and serum creatinine elevation were associated with a greater loss of calcitriol-mediated PTH suppression. The present findings differ from other studies in that calcitriol was still able to suppress PTH at 4 weeks of CKD.³³ The more prolonged responsiveness
could be because the generation of CKD through adenine induction is achieved more gradually than that obtained using 5/6 nephrectomy. In a previous study using this adenine model, calcitriol treatment was given to animals with less severe disease (according to serum creatinine levels) and was found to have greater effectiveness. In the present study, the diminished suppression is likely multifactorial but could include changes within the parathyroid gland itself. For example, hyperplasia of the parathyroid gland can result in a decline in VDR density and be a primary cause of the attenuated PTH response. Despite that the current treatments were initiated during a responsive phase, none of the four calcitriol protocols were able to prevent this decline in effectiveness. Further studies to characterize the changes in underlying mechanisms of this phenomenon in relation to CKD severity are needed.

All calcitriol treatments, regardless of the dosing profile, increased the VWF-associated endothelial dysfunction, enhanced FGF-23 levels, and exacerbated the severity of VC in all blood vessels. The significant increases in FGF-23 and VC were expected as similar findings were previously reported in this adenine model. The differences in the ratio of PTH to FGF-23 provided evidence of a dose-response profile within the treatment groups. Specifically, the ratio declined progressively from once a day 20 ng/kg, to the divided
dose calcitriol to the two high-dose paradigms. What was also evident was that unlike the rising trajectory of the individual hormones the ratio did not significantly change at any dose between 1 and 3 weeks. This latter finding suggests that a pharmacological steady state had been reached but the disease progression continued to drive hormonal changes. An unexpected finding was the minimal difference found between the different dosing regimens. The half-life of calcitriol in rats is 5–8 hours\(^40\),\(^41\) such that the lower dose (5 and 20 ng/kg, QID) given four times per day was expected to produce a different pattern compared to the single high doses (20 and 80 ng/}

\[\begin{align*}
\text{FIGURE 4} & \quad \text{Sub-analysis of serum PTH (A), FGF-23 (B), aortic tissue phosphate (C), and calcium (D) after calcitriol treatment in CKD rats based on stratification of PTH response. Untreated CKD rats (black circles, } n = 7), \text{ Minimal Suppression (MS, white upward triangle, } n = 13), \text{ Target Suppression (Target, gray diamond, } n = 14), \text{ Over Suppression (OS, black downward triangle, } n = 6). \text{ Multiple comparisons test with Bonferroni correction to test within-group differences. } ^{3}P < .05 \text{ Target significantly different than untreated CKD;} ^{**}P < .01 \text{ and } ^{***}P < .001 \text{ OS significantly different than untreated CKD;} ^{0}P < .01 \text{ and } ^{0.0}P < .001 \text{ Target significantly different than MS;} ^{A}P < .05 \text{ and } ^{A.0}P < .001 \text{ all groups significantly different than untreated CKD. Dark shaded area represents therapeutic target PTH range (A, 2–9× normal control range), light shaded area represents control range (C, D). The horizontal line represents levels of PTH and FGF-23 in healthy Controls (mean ± SD; 186.90 ± 52.67 and 338.93 ± 30.33, respectively). Data represented as mean ± SD.}
\end{align*}\]

\[\begin{align*}
\text{FIGURE 5} & \quad \text{Circulating vitamin D metabolites at study endpoint. Total 25-OH-D3 levels (A), total 24,25-(OH)2D3 levels (B), ratio of 24,25-(OH)2-D3 to 25-(OH)2-D3 levels (C), 1,25-(OH)2D3 levels (D). Shaded area represents range of values from healthy animals. Multiple comparisons test with Bonferroni correction to test within-group differences. } ^{*}P < .05, ^{**}P < .01 \text{ significantly different than untreated CKD.} ^{†}P < .05, ^{††}P < .01, ^{†††}P < .001 \text{ 20 ng/kg/day significantly different than 20 ng/kg/day. Data represented as mean ± SD. Shaded area represents range of values from healthy animals (Mean ± SD).}
\end{align*}\]
kg, SD) given once per day. There have been conflicting reports from studies using calcitriol in vivo, with respect to alterations in the prevalence of VC in experimental CKD. Some studies have found protective effects, whereas others have found accelerated pathogenesis using similar doses of calcitriol. 12,14–16,42

VWF is released in response to shear force and damage to the vascular endothelium. Supporting the present findings, increased VWF with progressing VC has previously been shown in experimental CKD. 43 Although the present findings conflict with previous studies suggesting that VDR activation is associated with better endothelial function, 44 taken together these data suggest that the specifics of the condition need to be taken into account before assuming either a benefit or an adverse effect will occur. The present results provide strong evidence that the increased VWF levels are associated with the calcitriol-mediated progression of aortic mineralization and not from an off-target action of calcitriol. The similar impact on VWF across all the stratified suppression states demonstrates a lack of direct impact of calcitriol on endothelial release of VWF. The increases are more likely due to the magnitude of the VC acting to change the hemodynamic properties of the vessel. Although further studies will be required to confirm the basis of this change, the early approximately two-fold increase in VWF in all calcitriol groups after only 1 week suggests this endothelial effect may indicate a yet unknown insult to the endothelium brought on by calcitriol treatment or an earlier initiation of VC. As such, the present study does provide further indication that elevations in circulating VWF in CKD can be used to identify not only endothelial dysfunction but also the occurrence of medial layer VC and that calcitriol treatment potentiates these developments experimentally.

Although there was a similar pathogenic impact of the four calcitriol protocols on VC, VWF, and FGF-23, changes within the vitamin D metabolome appeared to be much more dose-dependent. Specifically, calcitriol treatment increases circulating levels of 1,25-(OH)2D3, as expected, and reduced that of the endogenous precursor, 25-OH-D3, and associated metabolite 24,25-(OH)2D3 in a dose-dependent manner. The calcitriol-mediated reduction in the levels of 25-OH-D3 likely results from a negative feedback response producing changes in the levels of enzymes involved in synthesis and/or degradation. 45 Given that the ratio of 25-OH-D3 to 24,25-(OH)2D3 was not altered suggests that a full analysis of the pathways affected with the various calcitriol dosing strategies, there were no significant differences in the levels of FGF-23 induction or VC according to this stratification. These findings suggest that modifying calcitriol treatment strategies in this experimental CKD is insufficient to gain additional benefit beyond PTH suppression.

One conclusion of this study is that PTH suppression status alone does not sufficiently assess the impact of calcitriol treatment in CKD with mineral-bone disorder (CKD-MBD). Given the variety of changing factors that occur with CKD-MBD using multiple serum indicators (PTH and FGF-23 alone and/or ratio, calcium, and phosphate) as well as vascular health status (eg, CAC imaging, VWF levels, lumbar spine X-ray) be integrated to determine calcitriol treatment efficacy in CKD-MBD. Additionally, given the effects of PTH on bone resorption, examining changes to bone health and function may need to be incorporated; an area not examined within the present study due to experimental design limitations. VDR agonist use remains a prominent strategy for managing progressive and severe SHPT in CKD. 3 However, the potential for adverse effects of this therapy suggests that further refinement is clearly needed. 46,47 Although retrospective clinical studies report survival benefits and reduced CVD in patients given VDR agonists, 48,49 there are no prospective randomized clinical

![FIGURE 6 Sub-analysis of circulating vitamin D metabolites at study endpoint stratified based on PTH response to calcitriol treatment Total 25-OH-D3 levels (A), total 24,25-(OH)2D3 levels (B), ratio of 24,25-(OH)2D3 to 25-(OH)2D3 levels (C), 1,25-(OH)2D3 levels (D). Multiple comparisons test with Bonferroni correction to test within-group differences. *P < .05, **P < .01 significantly different than untreated CKD. *P < .05, significantly different than Minimal Suppression (MS). Data represented as mean ± SD. Shaded area represents range of values from healthy animals (Mean ± SD).]
trials, particularly in pre-dialysis patients, to show a benefit of direct-acting VDR agonists. As with rodent studies, the balance of results does not indicate cardiovascular benefit.

In conclusion, the present findings demonstrate that all calcitriol treatment strategies, regardless of changes to the treatment profile, lost the ability to sustain long-term PTH control as well as promoting adverse outcomes (increased VC, VWF and FGF-23). Thus, the concept that a benefit could be achieved by decreasing the peaks in circulating levels of calcitriol was not borne out. That is, the potential for a sustained release formulation of a direct-acting VDR agonist to provide greater benefit in terms of PTH control as well as decrease negative off-target outcomes was not supported. Specifically, the loss of efficacy at suppressing PTH in combination with the untoward effects on CKD-MBD suggests a controlled local production of active vitamin D or treatments which modify the sensitivity of the parathyroid gland sensitivity to calcium.

DATA SHARING AND DATA ACCESSIBILITY
The results in this paper were attained via an in vivo study and did not employ the use of a public repository. Said results have not been uploaded or made accessible to a public repository.

ACKNOWLEDGMENT
This manuscript was in part supported by grants from the Canadian Institute of Health Research and the National Sciences and Engineering Research Council of Canada.

CONFLICTS OF INTEREST
This research was funded by a 5-year operating grant from the Canadian Institutes of Health Research. Michael A. Adams and Rachel Holden are currently in receipt of an investigator-initiated research grant from OPKO Health Inc Renal Division for a different project involving treatments for adenine-induced CKD. Martin Petkovich is both a Professor at Queen’s University and the current Chief Scientific Officer for OPKO Health Inc Renal Division.

AUTHORS’ CONTRIBUTIONS
Technical assistance was provided by Cynthia Pruss, Martin Kaufmann, and Glenville Jones pertaining to serum/plasma analysis. Jason Zelt helped with study design. Kimberly Laverty provided technical assistance with animal handling, daily checks, and tissue collection. Martin Petkovich assisted with manuscript editing. Rachel Holden and Michael Adams assisted with study design, analysis, and editing of the manuscript.

ORCID
Bruno A. Svaiger https://orcid.org/0000-0001-6697-6004
Cynthia M. Pruss https://orcid.org/0000-0002-3841-8336
Jason G. E. Zelt https://orcid.org/0000-0001-8805-7025

REFERENCES
1. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. *Kidney Int*. 2007;71(1):31-38. https://doi.org/10.1038/sj.ki.5002009
2. Andrews DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. *Kidney Int*. 2006;69(1):33-43. https://doi.org/10.1038/sj.ki.5000405
3. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. *Kidney Int*. 2017;92(1):26-36. https://doi.org/10.1016/j.kint.2017.04.006
4. Pludowski P, Holick MF, Grant WB, et al. Vitamin D supplementation guidelines. *J Steroid Biochem Mol Biol*. 2018;175:125-135. https://doi.org/10.1016/j.jsbmb.2017.01.021
5. Rusinska A, Pludowski P, Walczak M, et al. Vitamin D supplementation guidelines for general population and groups at risk of Vitamin D deficiency in Poland-recommendations of the polish society of pediatric endocrinology and diabetes and the expert panel with participation of national specialist consultants and representatives of scientific societies-2018 update. *Front Endocrinol (Lausanne)*. 2018;9(248):246. https://doi.org/10.3389/fendo.2018.00246
6. Shoji T, Emoto M, Shinohara K, et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. *J Am Soc Nephrol*. 2001;12(10):2117-2124.
7. Tayebjee MH, Lip GY, Blann AD, Macfadyen RJ. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. *Thromb Res*. 2005;115(5):205-210. https://doi.org/10.1016/j.thromres.2004.08.023
8. Teng M, Wolb M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. *J Am Soc Nephrol*. 2005;16(4):1115-1125. https://doi.org/10.1681/ASN.2004070573
9. Faull C, Amaral AP, Oskoei B, et al. FGF23 induces left ventricular hypertrophy. *J Clin Investig*. 2011;121(11):4393-4408. https://doi.org/10.1172/JCI46122.ease
10. Leifheit-Nestler M, Grosse Siemer R, Flasbart K, et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. *Nephrol Dial Transplant*. 2016;31(7):1088-1099. https://doi.org/10.1093/ndt/gfv421
11. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol*. 2004;15(8):2208-2218. https://doi.org/10.1097/01.ASN.0000133041.27682.A2
12. Cardus A, Panizo S, Pariés E, Fernandez E, Valdivielso JM. Differential effects of vitamin D analogs on vascular calcification. *Bone Miner Res*. 2007;22(6):860-866. https://doi.org/10.1359/jbmr.070305
13. Zebger-Gong H, Muller D, Diercke M, et al. 1,25-Dihydroxyvitamin D3-induced aortic calcifications in experimental uremia: up-regulation of osteoblast markers, calcium-transporting proteins and osterix. *J Hypertens*. 2011;29(2):339-348. https://doi.org/10.1097/HJH.0b013e282340aa30
14. Lomashvili KA, Wang X, O’Neill WC. Role of local versus systemic vitamin D receptors in vascular calcification. *Arterioscler Thromb Vasc Biol*. 2014;34(1):146-151. https://doi.org/10.1161/ATVBAHA.113.302525
15. McCabe KM, Zelt JG, Kaufmann M, et al. Calcitriol accelerates vascular calcification irrespective of Vitamin K status in a rat model of chronic kidney disease with hyperphosphatemia and secondary
21. Petkovich M, Melnick J, White J, Tabash S, Strugnell S, Bishop A. Magnesium modifies the secretion of endogenous parathyroid hormone-related peptide. Circulation. 1998;98(13):1302-1306. https://doi.org/10.1161/01.CIR.98.13.1302

16. Zelt JG, McCabe KM, Svajger E et al. Magnesium modifies the effect of calcitriol on vascular calcification in experimental chronic kidney disease. J Pharmacol Exp Ther. 2013;355(3):451-462. https://doi.org/10.1124/jpet.112.230106

20. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators in vascular calcification in uremic rats. Kidney Int. 2007;72(6):709-715. https://doi.org/10.1086/500240

18. Lau WL, Leaf EM, Hu MC, et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int. 2012;82(12):1261-1270. https://doi.org/10.1038/ki.2012.322

19. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008;19(8):1509-1519. https://doi.org/10.1681/ASN.2007080902

22. Sprague SM, Crawford PW, Melnick JZ, et al. Use of extended-released calcefidel to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol. 2016;44(4):316-325. https://doi.org/10.1159/000450766

23. Sprague SM, Silva AL, Al-Saghir F, et al. Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol. 2014;40(6):535-545. https://doi.org/10.1159/000369939

24. Shobeiri N, Beseau D, Phelan R, Holden RM, Adams MA. The pathophysiology of vascular calcification in a rodent model of chronic kidney disease. FASEB J. 2010;24(1_supplement):116.113. https://doi.org/10.1096/fasebj.24.1_supplement.116.3

25. Knutson JC, Le Van LW, Valliere CR, Bishop CW. Pharmacokinetics and systemic effect on calcium homeostasis of 1α,24-dihydroxyvitamin D2 in rats comparison with 1α,25-Dihydroxyvitamin d2, calcitriol, and calcipotriol. Biochem Pharmacol. 1997;53(6):829-837. https://doi.org/10.1016/S0006-2952(97)00004-X

26. McCabe KM, Booth SL, Fu X, et al. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 2013;83(5):835-844. https://doi.org/10.1038/ki.2012.477

27. Kaufmann M, Gallagher JC, Peacock M, et al. Clinical utility of simultaneous quantitation of 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D by LC-MS/MS involving derivatization with DMEQ-TAD. J Clin Endocrinol Metab. 2014;99(7):2567-2574. https://doi.org/10.1205/jc.2013.4388

28. Kaufmann M, Lee SM, Pike JW, Jones G. A high-calcium and phosphate rescue diet and VDR-expressing transgenes normalize serum vitamin D metabolite profiles and renal Cyp27b1 and Cyp24a1 expression in VDR null mice. Endocrinology. 2015;156(12):4388-4397. https://doi.org/10.1205/en.2015.1664

29. Kaufmann M, Prosser DE, Jones G. Bioengineering anabolic Vitamin D-25-hydroxylase activity into the human Vitamin D catabolic enzyme, cytochrome P450 CYP24A1, by a V391L mutation. J Biol Chem. 2011;286(33):28729-28737. Retrieved from http://www.jbc.org/content/286/33/28729.abstract

30. Laha TJ, Strathmann FG, Wang Z, de Boer IH, Thummler KE, Hoofnagle AN. Characterizing antibody cross-reactivity for immunofinity purification of analytes prior to multiplexed liquid chromatography-tandem mass spectrometry. Clin Chem. 2012;58(12):1711. Retrieved from http://clinchem.aaccjnl.org/content/58/12/1711.abstract

31. Shobeiri N, Adams MA, Holden RM. Vascular calcification in animal models of CKD: a review. Am J Nephrol. 2010;31(6):471-481. https://doi.org/10.1159/000299794

32. Zelt JG, Svajger BA, Quinn K, et al. Acute tissue mineral deposition in response to a phosphate pulse in experimental CKD. J Bone Miner Res. 2018;34(2):270-281. https://doi.org/10.1002/jbmr.3572

33. Arcidiacono MV, Sato T, Alvarez-Hernandez D, et al. EGRF activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol. 2008;19(2):310-320. https://doi.org/10.1681/ASN.2007040406

34. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92(3):1436-1443. https://doi.org/10.1172/JCI116720

35. Brown AJ, Ritter CS, Finch JL, Slatopolsky EA. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int. 1999;55(4):1284-1292. https://doi.org/10.1046/j.1523-1755.1999.00386.x

36. Cozzolino M, Lu Y, Sato T, et al. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol. 2005;289(5):F1096-1102. https://doi.org/10.1152/ajprenal.n.00167.2005

37. Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis. 1996;28(4):596-602. https://doi.org/10.1016/S0272-6386(96)90473-4

38. Shobeini NS. Characterization of vascular calcification in a rodent model of chronic kidney disease. (Master of Science). Kingston, ON: Queen's University; 2009.

39. Fukagawa M, Fukuda N, Yi H, Kurokawa K. Resistance of parathyroid cell to calcitriol as a cause of parathyroid hyperfunction in chronic renal failure. Nephrol Dial Transplant. 1995;10(3):316-319. https://doi.org/10.1093/oxfordjournals.ndt.a091092

40. Preissner S, Kroll K, Dunkel M, et al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010;38(suppl 1):D237-D243. https://doi.org/10.1093/nar/gkp970

41. Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011;1814(1):186-199. https://doi.org/10.1016/j.bbadis.2010.06.022

42. Jung S, Querfeld U, Muller D, Rudolph B, Peters H, Kramer S. Submaximal suppression of parathyroid hormone ameliorates calcitriol-induced aortic calcification and remodeling and myocardial fibrosis in uremic rats. J Hypertens. 2012;30(11):2182-2191. https://doi.org/10.1097/1HJH.0b013e32835704f9

43. Maio MT, McCabe KM, Pruss CM, et al. Calcification of the internal pudendal artery and development of erectile dysfunction in adenine-induced chronic kidney disease: a sentinel of systemic vascular changes. J Sex Med. 2014;11(10):2449-2465. https://doi.org/10.1111/jsm.12648

44. Chitalia N, Recio-Mayoral A, Kaski JC, Banerjee D. Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis. 2012;220(1):265-268. https://doi.org/10.1016/j.atherosclerosis.2011.10.023

45. Helvig CF, Guerrier D, Hosfield CM, et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int. 2010;78(5):463-472. https://doi.org/10.1038/ki.2010.168
46. Mallick NP, Berlyne GM. Arterial calcification after vitamin-D therapy in hyperphosphatemic renal failure. Lancet. 1968;2(7582):1316-1320. https://doi.org/10.1016/S0140-6736(68)91816-3

47. Mann MC, Hobbs AJ, Hemmelgarn BR, Roberts DJ, Ahmed SB, Rabi DM. Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. Clin Kidney J. 2015;8(1):41-48. https://doi.org/10.1093/ckj/sfu122

48. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008;168(4):397-403. https://doi.org/10.1001/archinternmed.2007.110

49. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondia-lyzed CKD. J Am Soc Nephrol. 2008;19(8):1613-1619. https://doi.org/10.1681/ASN.2007111164

How to cite this article: Svajger BA, Pruss CM, Laverty KJ, et al. PTH suppression by calcitriol does not predict off-target actions in experimental CKD. Pharmacol Res Perspect. 2020;e00605. https://doi.org/10.1002/prp2.605